Cancer News
OncoLink Cancer News - HealthDay


Some 10 million Americans have actinic keratoses

-- Scott Roberts

Friday, March 26, 2010 (Last Updated: 03/29/2010)

FRIDAY, March 26 (HealthDay News) -- Zyclara topical cream (imiquimod 3.75 percent) has been approved by the U.S. Food and Drug Administration to treat actinic keratoses (AKs), a precancerous condition that's commonly found on skin frequently exposed to the sun.

AKs -- sometimes confused with eczema or psoriasis -- are small, red patches of skin that also may be scaly or rough, drug maker Graceway Pharmaceuticals said. They are most often found on the face, bald scalp, hands, shoulders and arms. Some 10 million Americans have the condition, which tends to recur, the company said in a news release.

AKs should be treated without delay, since they may progress to a form of skin cancer called squamous cell carcinoma. In clinical testing involving people with five to 20 AKs on the face or scalp, Zyclara reduced the total number of AKs by 82 percent, the news release said.

The most common side effects reported were local skin reactions with redness, scabbing or crusting, and sores or ulcers.

More information

To learn more about actinic keratoses, visit the Skin Cancer Foundation.

Specialties Oncology
OBGYN & Women's Health

Copyright © 2010 HealthDay. All rights reserved.


I Wish You Knew

The rewards of working in radiation oncology

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More